HC Wainwright Has Negative Outlook for MNMD Q3 Earnings

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Free Report) - Stock analysts at HC Wainwright dropped their Q3 2025 earnings per share estimates for shares of Mind Medicine (MindMed) in a research report issued to clients and investors on Wednesday, May 21st. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.36) for the quarter, down from their previous estimate of ($0.35). HC Wainwright currently has a "Buy" rating and a $55.00 target price on the stock. The consensus estimate for Mind Medicine (MindMed)'s current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for Mind Medicine (MindMed)'s FY2025 earnings at ($1.32) EPS and FY2027 earnings at ($1.31) EPS.

Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.01.

Several other equities research analysts have also weighed in on the company. Cantor Fitzgerald raised Mind Medicine (MindMed) to a "strong-buy" rating in a research report on Tuesday, May 13th. Robert W. Baird cut their target price on Mind Medicine (MindMed) from $27.00 to $16.00 and set an "outperform" rating on the stock in a research report on Friday, March 7th. Evercore ISI began coverage on Mind Medicine (MindMed) in a research report on Tuesday, January 28th. They set an "outperform" rating and a $23.00 target price on the stock. Finally, Chardan Capital reissued a "buy" rating and set a $20.00 target price on shares of Mind Medicine (MindMed) in a research report on Friday, May 9th. Nine research analysts have rated the stock with a buy rating and four have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Mind Medicine (MindMed) has a consensus rating of "Buy" and an average price target of $25.11.

Mind Medicine (MindMed) Stock Up 0.1%

Shares of MNMD traded up $0.01 during midday trading on Monday, hitting $7.15. The company had a trading volume of 869,260 shares, compared to its average volume of 1,392,730. The company's 50-day simple moving average is $6.22 and its 200-day simple moving average is $6.97. The company has a debt-to-equity ratio of 0.09, a quick ratio of 9.00 and a current ratio of 9.00. The firm has a market capitalization of $538.88 million, a P/E ratio of -3.16 and a beta of 2.52. Mind Medicine has a 1 year low of $4.70 and a 1 year high of $10.44.

Insiders Place Their Bets

In other Mind Medicine (MindMed) news, insider Daniel Karlin sold 6,836 shares of Mind Medicine (MindMed) stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $6.74, for a total transaction of $46,074.64. Following the transaction, the insider now owns 446,177 shares of the company's stock, valued at $3,007,232.98. The trade was a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Robert Barrow sold 21,208 shares of Mind Medicine (MindMed) stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $6.74, for a total value of $142,941.92. Following the transaction, the chief executive officer now directly owns 856,556 shares in the company, valued at approximately $5,773,187.44. This trade represents a 2.42% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,391 shares of company stock valued at $204,835 over the last quarter. Company insiders own 2.45% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Diadema Partners LP purchased a new position in shares of Mind Medicine (MindMed) in the 4th quarter valued at approximately $33,000. Hollencrest Capital Management grew its stake in shares of Mind Medicine (MindMed) by 10,833.3% in the 4th quarter. Hollencrest Capital Management now owns 7,216 shares of the company's stock valued at $50,000 after purchasing an additional 7,150 shares during the last quarter. Black Swift Group LLC purchased a new position in shares of Mind Medicine (MindMed) in the 1st quarter valued at approximately $63,000. CreativeOne Wealth LLC purchased a new position in shares of Mind Medicine (MindMed) in the 1st quarter valued at approximately $67,000. Finally, King Wealth Management Group purchased a new position in shares of Mind Medicine (MindMed) in the 4th quarter valued at approximately $70,000. Institutional investors and hedge funds own 27.91% of the company's stock.

About Mind Medicine (MindMed)

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.